Pakistan Abridged Evaluation Pathway: Leveraging FDA and CE Approvals

1. Key takeaways

Foreign devices already approved by a reference regulatory authority may qualify for the Abridged Evaluation Pathway. Usable reference approvals include: US FDA (510(k) / PMA), EU MDR / IVDR CE marking, Japan PMDA, Australia TGA, Canada Health Canada, UK MHRA / UKCA, as well as WHO prequalification and a CE mark issued by a conformity assessment body (CAB) notified in the NANDO database. Where the pathway applies, both the technical documentation requirements and the administrative processing timelines can be compressed significantly. The pathway converts existing approvals into regulatory credit — but only when the underlying evidence is current and properly submitted. For sponsors holding one of the listed approvals, the planning question is therefore not whether the pathway exists but whether their specific evidence package can carry it: which certificate will be relied on, whether it maps to a listed jurisdiction or route, and whether its expiry horizon comfortably covers the expected review and the 5-year certificate life that follows.

• The abridged pathway is built on Rule 15(2) of the Medical Devices Rules, 2017, which lets the MDB issue certificates based on reference-authority registration.
• The qualifying approvals span FDA 510(k) / PMA, CE under MDR / IVDR, PMDA, TGA, Health Canada, MHRA / UKCA, WHO prequalification and NANDO-notified CAB CE marks.
• Compression applies to both the technical documentation set and the administrative timeline — but nothing is waived from submission.
• The companion benefit is the premises inspection exemption under Rule 15(1), which in practice often matters more than speed.

2. Legal basis

The abridged pathway rests on the same provision that defines the reference-authority list, together with the general technical duties that continue to apply to all registration dossiers. The table below sets out the mapping; note that Rule 14(5) and Rule 14(6) are not switched off by reliance — they apply in full.

3. Expert insights

Insight one: the core value of the abridged pathway is not only speed but avoiding the factory audit. Rule 15(1) states the exemption in terms. For foreign manufacturers, the value of avoiding a cross-border factory inspection often exceeds the time saved itself. A DRAP visit means scheduling, hosting, document staging and the operational disruption of preparing a site for a foreign regulator — costs that recur with every audit and that the exemption removes entirely for qualifying products. Speed can be recovered with effort; an audit, once scheduled, must simply be endured. This is why GRZAN treats the exemption as a primary project benefit in client planning rather than a footnote to the timeline discussion, and why the eligibility of a product for the exemption is confirmed before pathway selection is finalised.

Insight two: abridged does not mean exempt from submission. The wording of Rule 15(2) is that registration shall be based on the registration by the reference authority, and it still requires the applicant to submit the existing evidence. Reading it as meaning no documents are needed once a CE mark exists is wrong. The authority relies on the external conclusion, but it relies on the conclusion as presented in the file — which means the evidence must be attached, legible, current and consistent with the device described in the dossier. Reliance shifts the depth of review, not the duty to produce the record. In practice this distinction shows up at intake: a file that claims reliance but omits the certificate it names is simply an incomplete file, and the completeness rules apply to it exactly as they would to a full dossier.

Insight three: reference-country approvals must be usable and within their validity period. Registration practice compilation repeatedly flags this: expired ISO certificates and lapsed CE certificates are common return reasons. Maintaining reference-country evidence is a long-term commitment in a Pakistan project, not a one-time action before submission. A dossier built on a certificate that expires mid-review creates a gap the authority can act on, so the expiry calendar must run alongside the review clock, not independently of it. The same discipline extends through the certificate life: the Pakistan registration itself runs for 5 years, which is long enough for several underlying certificates to come up for renewal, and each renewal must land on time for the reliance foundation to stay intact.

4. Practical recommendations

GRZAN manages reference-country evidence on a standing maintenance list: the validity periods of CE certificates, ISO 13485 certificates and FSC documents are each registered, with reminders set 12 months before expiry. The list is reviewed before any Pakistani filing event, so evidence currency is verified as a precondition rather than discovered as a defect.

• Register every CE certificate, ISO 13485 certificate and FSC on the standing maintenance list, with its validity period recorded against it.
• Set reminders 12 months before each expiry, so renewals are initiated while the old evidence still stands.
• Before every Pakistani renewal or variation, re-verify the current validity status of all evidence first, then file.
• Treat this habit as the antidote to the majority of evidence-expired return notices — it prevents almost every return of the expired-document type.
• Keep the submitted evidence set aligned with the device described in the dossier, so the reliance reading holds on inspection of the file.

5. Verification checklist

• □ At least one usable reference-country approval evidence item has been prepared
• □ All evidence items are within their validity periods
• □ The CE evidence can be traced to a specific member state and CAB
• □ Evidence validity periods have been entered on the standing maintenance list
• □ Evidence status has been re-checked before renewal and variation filings

Regulatory information verified as of 28 October 2026.

How GRZAN can help. GRZAN provides medical device and IVD registration, quality system, authorised representative and local testing support across South Asia, including Pakistan. Our team prepares dossiers to DRAP expectations, manages eCTD-format submissions and deficiency responses, and supports post-market vigilance obligations. Business enquiries: info@grzanglobal.com